Publications database

Despite its great promise, implementation of CAR-T therapy-a personalized, logistically complex, and expensive treatment-remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU-approved) for 15 hematologic malignancy indications. [...]

Complete tumor resection is crucial in oncological liver surgery, and the evaluation of intraoperative resection margins is essential to prove R0 resection. This can be challenging for hepatocellular carcinoma (HCC) due to the heterogeneity of both the tumor and background liver tissue. [...]

The Barcelona Clinic Liver Cancer (BCLC) classification has been the mainstay for prognostic assessment and initial treatment selection in hepatocellular carcinoma (HCC) for more than two decades. It is widely clinically accepted and has been reaffirmed in the recently renewed European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on the management of HCC. [...]

Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).A retrospective chart review was conducted in adult patients with stage III/IV melanoma who initiated anti-PD-1 therapy from January 2018 until 12 months before the start of data collection at 22 sites across six countries. [...]

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR+/HER2- locally advanced/metastatic breast cancer (aBC). The CDK4/6i ribociclib in combination with an aromatase inhibitor (AI) or fulvestrant (FUL) has demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits for pre- and postmenopausal aBC patients who were enrolled in the three pivotal MONALEESA trials. [...]

Low nephron endowment constitutes a risk factor for hypertension and renal disease. Epigenetic regulation is crucial for nephron progenitor cell differentiation, affecting nephron number and renal function. [...]

We assessed clinical features, treatment, and survival of pediatric patients with neurofibromatosis type 1 (NF1) with high-grade glioma (HGG).Patients from this retrospective cohort study were identified through an international collaborative effort by the SIOPE HGG/DIPG working group. NF1 was diagnosed based on clinical presentation and confirmed by either a pathogenic germline NF1 gene alteration or the exclusion of mismatch repair deficiency. [...]

[This corrects the article DOI: 10.3389/fonc.2024.1417862.]..

Artificial intelligence (AI) is transforming the diagnostic landscape of malignant tumors in the urinary system, including prostate cancer, bladder cancer, and renal cell carcinoma (RCC). By integrating imaging, pathology, and molecular data, AI enhances the precision and reproducibility of tumor detection, grading, and risk stratification. [...]

Background:Postoperative pancreatic fistula (POPF) remains the most common and impactfulcomplication after distal (left) pancreatectomy (DP). While previous studies haveidentified histological features such as acinar cell content and fibrosis as risk factors forPOPF after pancreatoduodenectomy (PD), their relevance in DP remains unclear. [...]